Ask AI
ProCE Banner Activity

Phase II Trial of Weekly Oral ISL + LEN for People Living With Virologically Suppressed HIV: Early and Late Switch Results 

Conference Coverage
Slideset

In this open-label phase II study, adults with virologically suppressed HIV who received once-weekly oral islatravir plus lenacapavir sustained high levels of viral suppression and adherence through Week 96. No meaningful changes in weight or BMI were observed through Week 96, and CD4+ T-cell and lymphocyte counts remained stable through Week 108.

Released: March 03, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions